PMID- 12190098
OWN - NLM
STAT- MEDLINE
DCOM- 20030116
LR  - 20151119
IS  - 0036-5521 (Print)
IS  - 0036-5521 (Linking)
VI  - 37
IP  - 7
DP  - 2002 Jul
TI  - Profile of monocyte chemoattractant protein-1 circulating levels in gastric 
      cancer patients.
PG  - 830-3
AB  - BACKGROUND: Monocyte chemoattractant protein-1 (MCP-1) has been shown to act as a 
      chemokine in the recruitment of monocyte/macrophages during inflammation states. 
      It acts as an important factor in the cytokine network, which regulates tumor 
      proliferation, whereas the association between serum MCP-1 level and gastric 
      cancer has not yet been clarified. METHODS: The serum concentration of MCP-1 in 
      76 gastric cancer patients and in 45 normal controls was determined using an 
      immunoradiometric assay. The concentration of MCP-1 in the 47 cancer tissue 
      samples was also determined. RESULTS: The serum concentration of MCP-1 in 
      patients with advanced carcinoma was significantly lower than that in controls. 
      The serum concentration of MCP-1 in patients with advanced carcinoma was 
      significantly lower than that in patients with early carcinoma. The serum 
      concentration of MCP-1 was associated with clinicopathological factors including 
      lymph node metastasis, serosal invasion and histological differentiation of the 
      tumor. In patients who underwent palliative surgery, the serum MCP-1 level 
      significantly decreased postoperatively, whereas in patients who underwent 
      curative surgery the serum MCP-1 level tended to increase. The 4-year survival 
      rate in patients whose serum MCP-1 levels were lower than or equal to the median 
      value was significantly lower than that in patients whose MCP-1 levels were 
      higher than the median value. The tissue concentration of MCP-1 in the cancer 
      tended to decrease in accordance with disease progression. CONCLUSIONS: The serum 
      level of MCP-1 decreased in accord with disease progression, which reflects local 
      consumption in gastric cancer. Serum MCP-1 may be a useful marker that reflects 
      the host's local resistance to the tumor.
FAU - Tonouchi, H
AU  - Tonouchi H
AD  - Dept of Innovative Surgery, Mie University Medical School, Tsu, Japan. 
      tonouchi@clin.medic.mie-u.ac.jp
FAU - Miki, C
AU  - Miki C
FAU - Tanaka, K
AU  - Tanaka K
FAU - Kusunoki, M
AU  - Kusunoki M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Scand J Gastroenterol
JT  - Scandinavian journal of gastroenterology
JID - 0060105
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Neoplasm Proteins)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/*blood
MH  - Chemokine CCL2/*blood
MH  - Disease Progression
MH  - Female
MH  - Gastrectomy
MH  - Humans
MH  - Immunoradiometric Assay
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Proteins
MH  - Neoplasm Staging
MH  - Stomach Neoplasms/*blood
MH  - Survival Analysis
EDAT- 2002/08/23 10:00
MHDA- 2003/01/17 04:00
CRDT- 2002/08/23 10:00
PHST- 2002/08/23 10:00 [pubmed]
PHST- 2003/01/17 04:00 [medline]
PHST- 2002/08/23 10:00 [entrez]
PST - ppublish
SO  - Scand J Gastroenterol. 2002 Jul;37(7):830-3.